InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$145.97

2026-10-16

Market Cap

$360.1B

Volume

11.1M

52-Wk High

$156.92

52-Wk Low

$82.01

Trailing PE

115.8

P/S

5.42

Gross Margin

75.4%

Net Margin

4.8%

ROE

7%

ROIC

6%

Piotroski

5/9

Altman Z

3.9

1-Yr Return

+75.4%

5-Yr Return

+119.0%

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNYSEMarket Cap$360.1BEmployees75,000 (SEC-filed)CEORobert DavisIPO1978-01-13CountryUS

126 East Lincoln Avenue, Rahway, NJ 07065 · Tel 908 740 4000 · merck.com

INSIDERSTREET SCORE49 / 100Street mean $155.41 (22 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$26M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · MRK +75.4% · S&P 500 +15.9% · spread +59.5pp

7 Years vs S&P 500 · MRK +119.0% · S&P 500 +189.9% · spread -70.9pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE49of 100

Score Breakdown

Profitability	28/100
Growth	24/100
Momentum	58/100
Quality	55/100
Earnings Quality	54/100
Balance Sheet	45/100
Value	36/100
Risk (safety)	90/100
Overall	48.9/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
NVS	65
ABBV	67
AZN	71
AMGN	67
JNJ	64
GILD	44
MRK	49

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 81 in 24 Q4, latest 49 — -32 since. Dropped below the 55 line in 26 Q1, at 49. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY49 / 100IS Score 48.9 / 100 · -31.8 from peak of 81

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURELEAN BULLISHTechnical Score 60 / 100 · Power +21 · 15 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 49, price structure 60 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 48.9	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 70 → 60 → 49 → 49	the direction matters more than the level
Technical vote share back above 50%	now 73%	price structure no longer broken
Institutional holder count rises two quarters running	peak 3,805 → now 3,805	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)4 buys2026-08-19

Insider Buys (180d)0none disclosed

ETF Funds (30d)1907 up / 1612 downnet +295 funds

Institutions Added (13F)47managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 3,805 · latest 3,805 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	3,805	2030.0M	$254.5B	82.1%
2026 Q1	3,758	1927.8M	$225.9B	78.0%
2025 Q4	3,612	1955.3M	$201.1B	79.1%
2025 Q3	3,253	1946.6M	$156.3B	78.7%
2025 Q2	3,274	2002.5M	$152.7B	81.0%
2025 Q1	3,394	1980.3M	$177.2B	80.1%
2024 Q4	3,545	1971.0M	$192.7B	79.7%
2024 Q3	3,429	1949.0M	$216.4B	78.8%
2024 Q2	3,483	1946.9M	$235.8B	78.8%
2024 Q1	3,476	1940.2M	$249.1B	78.5%
2023 Q4	3,371	1928.9M	$206.1B	78.0%
2023 Q3	3,147	1908.6M	$193.2B	77.2%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Seidman Christine E	director	2026-09-30	A-Award	56	—	21,490
Karsanbhai Surendralal Lanca	director	2026-09-30	A-Award	112	—	5,667
Coe Mary Ellen	director	2026-09-30	A-Award	206	—	32,420
Gupta Gaurav K	EVP, CIDO	2026-09-01	—	19,443	—	0
Guindo Chirfi	EVP, Access, Policy & Comms	2026-08-13	SELL	10,000	$1.35M	36,613
Zachary Jennifer	EVP, General Counsel	2026-08-12	EXERCISE	41,494	$4.89M	112,391
Zachary Jennifer	EVP, General Counsel	2026-08-12	EXERCISE	13,433	$1.14M	125,824
Zachary Jennifer	EVP, General Counsel	2026-08-12	SELL	80,315	$10.72M	45,509

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	13	194,076	$25.6M	Counted
M — Exercises (paired A/D)	23	177,002	$17.1M	None — mechanics
F — Tax withholding	15	23,599	$2.6M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$25.6M13 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-13	Chirfi Guindo	10,000	$1.4M
2026-08-12	Jennifer L Zachary	80,315	$10.7M
2026-08-12	Richard Robert Deluca Jr	11,699	$1.5M
2026-08-11	Richard Robert Deluca Jr	12,837	$1.7M
Trailing 12 mo	23 filings	604,348	$74M

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.53%	186.3M sh
2025-03-06	SCHEDULE 13G/A	The Vanguard Group	10.02%	253.3M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Maria Elvira Salazar	House	SELL	$1,001 - $15,000	2026-09-24	2026-10-08
Ro Khanna	House	SELL	$1,001 - $15,000	2026-09-04	2026-10-09
Michael McCaul	House	SELL	$50,001 - $100,000	2026-08-28	2026-10-16
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2023-10-16	2023-11-16
Thomas Hawley Tuberville	Senate	SELL	$1,001 - $15,000	2023-10-16	2023-11-15
Pete Ricketts	Senate	SELL	$50,001 - $100,000	2023-09-21	2023-10-20

House 12-Mo28 trades13 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)3,758

13F Shares1.93B78.0% of shares out

New / Closed326 / 120positions, QoQ

Increased / Reduced1,447 / 1,558positions, QoQ

Put/Call (13F)0.97option positions

Free Float99.9%2.46B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Smead Capital Management, Inc.	2.3M	$335M
Wealth Enhancement Advisory Servic	1.8M	$232M
Assenagon Asset Management S.A.	1.6M	$228M
Fjarde Ap-Fonden /Fourth Swedish N	1.1M	$159M
Mn Services Vermogensbeheer B.V.	730,921	$106M
Sarasin & Partners Llp	711,274	$103M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.5%	$11.4B
VSMPX	0.5%	$11.4B
VTSAX	0.5%	$11.4B
VTI	0.5%	$11.4B
VFINX	0.5%	$9.4B
VFFSX	0.5%	$9.4B

13F Filers Holding MRK — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session41.1%2026-10-15

20-Day Avg34.0%50-day 41.2%

TrendFalling20d vs 50d

By Market CenterQ: 40% · N: 59% · B: 34%latest session

Weekly Notional ($B)

Where MRK Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	10.9M	68 sh
Ubsa Ubs Ats	9.7M	71 sh
Ebxl Level Ats	6.7M	40 sh
Pure Purestream	5.9M	54 sh
Sgmt Sigma X2	5.9M	70 sh
Mstx Ms Trajectory Cross (Ats-1)	4.8M	86 sh

Where a dollar of Merck & Co., Inc. revenue goes. All values FY2025 filings, live.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Region	Revenue	Share
UNITED STATES	$36.5B	56%
EMEA	$14.6B	22%
Latin America	$3.4B	5%
Asia Pacific	$3.0B	5%
International	$2.9B	4%
JAPAN	$2.7B	4%
CHINA	$1.9B	3%

MRK (live moat model)Peer median: NVS · ABBV · AZN · AMGN · JNJ

Component scores from the live moat model. Peer median illustrative.

Moat score 61/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Robert Davis	Chairman, President & Chief Executive Officer
Dean Y. Li	Executive Vice President & President of Merck Research Laboratories
Caroline Litchfield	Executive Vice President & Chief Financial Officer
Betty D. Larson	Executive Vice President & Chief Human Resources Officer

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+14.1%

Next Report2026-10-29

Income Quality6.30OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+17.3%	+21.7%	+1.4%	+6.7%	+1.3%
Gross profit	+25.7%	+19.4%	+5.1%	+11.3%	+8.2%
Operating income	+137.9%	+38.5%	-83.8%	+584.5%	+32.4%
Net income	+84.6%	+11.3%	-97.5%	+4589.6%	+6.6%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	48.7	59.3	60.1	64.2	65.0
Cost of revenue	13.6	17.4	16.1	15.2	12.0
Gross profit	35.1	41.9	44.0	49.0	53.0
R&D expense	12.2	13.5	30.5	17.9	15.6
SG&A expense	9.4	9.7	9.9	10.1	10.6
Operating income	13.2	18.3	3.0	20.2	26.8
EBITDA	17.9	21.3	6.9	25.7	25.4
D&A	3.2	3.9	3.9	4.5	4.3
Pretax income	13.9	16.4	1.9	19.9	21.1
Income tax	1.5	1.9	1.5	2.8	2.8
Net income	13.0	14.5	0.4	17.1	18.3
Diluted EPS ($)	5.14	5.71	0.14	6.74	7.28
Diluted shares (M)	2,538	2,542	2,547	2,541	2,507

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Operating CF$16B

CapEx$4B

Free cash flow$12B

SBC$0B

Buybacks$5B

Net cash change$1B

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	12.7	6.8	13.2	14.6
ST investments	0.5	0.3	0.4	0.0
Receivables (net)	9.5	10.3	10.3	12.7
Total current assets	35.7	32.2	38.8	43.5
PP&E (net)	21.4	23.1	23.8	26.8
Goodwill + intangibles	41.5	39.2	38.0	48.3
Total assets	109.2	106.7	117.1	136.9
Accounts payable	4.3	3.9	4.1	4.4
Short-term debt	1.9	1.4	2.6	2.9
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	24.2	25.7	28.4	28.3
Long-term debt	28.7	33.7	34.5	46.8
Total liabilities	63.1	69.0	70.7	84.2
Shareholders' equity	46.1	37.6	46.4	52.7

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	14.5	0.4	17.1	18.3
D&A	3.9	3.9	4.5	5.8
Stock-based compensation	0.5	0.6	0.8	0.0
Working capital change	(2.8)	(2.2)	(3.7)	(7.0)
Operating cash flow	19.1	13.0	21.5	16.5
Capital expenditures	(4.4)	(3.9)	(3.4)	(4.1)
Investing cash flow	(5.0)	(14.1)	(7.7)	(13.7)
Buybacks	0.0	(1.3)	(1.3)	(5.1)
Dividends paid	(7.0)	(7.4)	(7.8)	(8.2)
Debt issuance / (repay)	(2.3)	4.2	2.3	11.4
Financing cash flow	(9.1)	(4.8)	(7.0)	(1.9)
Free cash flow	14.7	9.1	18.1	12.4

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	41.1%	34.5%	0.9%	40.8%	36.9%	7%
ROA	13.2%	13.5%	0.3%	15.3%	14.4%	2.4%
ROIC	18.2%	24.9%	0.9%	24.5%	23.7%	5.6%
Gross margin	72.0%	70.6%	73.2%	76.3%	81.5%	75.4%
Operating margin	27.1%	30.8%	4.9%	31.5%	41.2%	16.7%
Net margin	26.8%	24.5%	0.6%	26.7%	28.1%	4.8%
EBITDA margin	36.8%	36.0%	11.5%	40.1%	39.0%	21.0%
FCF margin	19.8%	24.8%	15.2%	28.2%	19.0%	—
VALUATION
P/E	13.16	17.77	715.66	14.23	14.35	115.8
P/B	4.50	5.61	6.95	5.26	4.98	8.6
P/S	3.53	4.35	4.35	3.80	4.03	5.42
P/FCF	17.78	17.54	28.57	13.46	21.19	22.4
EV/EBITDA	11.08	12.98	42.04	10.43	10.54	29.2
EV/Revenue	4.07	4.67	4.83	4.18	4.59	6.1
Earnings yield	7.6%	5.6%	0.1%	7.0%	7.0%	0.88%
FCF yield	5.6%	5.7%	3.5%	7.4%	4.7%	4.46%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.27	1.47	1.25	1.36	1.54	1.32
Quick ratio	1.02	1.23	1.00	1.15	1.30	1.10
Debt / equity	0.91	0.70	0.97	0.83	0.96	1.29
Debt / assets	32.8%	29.3%	34.0%	32.7%	36.9%	41.5%
Net debt / EBITDA	1.48	0.88	4.22	0.96	1.27	3.38
Interest coverage	18.20	18.09	2.65	16.69	16.54	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.49	0.55	0.56	0.57	0.51	0.51
Receivables turnover	6.08	6.35	6.07	6.22	5.89	5.3
DSO (days)	60	58	60	59	62	69
DPO (days)	120	93	93	96	99	85
Cash conversion cycle	95	89	106	112	112	122
GROWTH (YoY)
Revenue growth	8.6%	21.7%	1.4%	6.7%	1.2%	—
Net income growth	84.6%	11.3%	-97.5%	4589.6%	6.6%	—
EPS growth	85.0%	10.7%	-97.5%	4613.9%	8.9%	—
FCF growth	73.5%	52.2%	-37.8%	97.9%	-31.7%	—
PER SHARE ($)
EPS (diluted, TTM)	5.15	5.70	0.14	6.74	7.34	1.28
Book value / share	15.06	18.05	14.71	18.23	21.14	16.98
Revenue / share	19.21	23.27	23.54	25.25	26.10	26.86
FCF / share	3.81	5.77	3.58	7.12	4.97	6.50
Cash / share	3.19	5.18	2.78	5.39	5.85	2.89
SHAREHOLDER RETURN & SCORES
Buyback yield	0.5%	0.0%	0.5%	0.5%	0.5%	0.12%
Altman Z-Score	3.23	4.43	3.71	4.07	3.76	3.9
Piotroski F-Score	9	8	5	9	4	5/9
Beneish M-Score	-2.25	-2.68	-2.95	-2.65	-2.11	-2.94

Model	Score	Zone	Note
Piotroski F-Score	5 / 9	Middling
Altman Z-Score	3.9	Safe (>2.99)	Safe
Income quality	6.30	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.94	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.53
Interest burden	0.82
Operating margin	10.8%
Asset turnover	0.54×
Financial leverage	2.72×
= ROE	7%

Growth Quality (live)	Value
Revenue stability	0.93
Earnings stability	0.00
Earnings persistence	0.50
Revenue CAGR 3y	4.5%
EPS CAGR 3y	1.6%
FCF CAGR 3y	14.0%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.12%

Dividend Yield2.33%

Total Shareholder Return2.66%cash yield

SBC / Revenue1.3%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
ABBV	$504.4B	80.4	-206%	21.3%	+10.4%	7/9	+25.8%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	+50.3%
JNJ	$615.9B	38.7	26%	21.9%	+8.1%	7/9	—
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	—
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	—
BMY	$122.1B	13.2	47%	25.6%	+3.1%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

38 Analysts

Str Sell (0)Sell (1)Hold (11)Buy (26)Str Buy (0)

Mean Target (qtr)$155.4122 targets

Target vs. Price+6.5%last-quarter mean

Next Report2026-10-29street $2.09

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$67.05B	$67.20B / $66.77B	$2.65	$2.75 / $2.49	14
FY2027	$69.77B	$71.72B / $68.81B	$9.28	$10.01 / $8.55	13
FY2028	$73.81B	$79.69B / $70.08B	$10.22	$12.21 / $8.02	8

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$156.67	+7.3%	3
Last Quarter	$155.41	+6.5%	22
Last Year	$142.28	-2.5%	46
All Time	$127.11	-12.9%	92

Rolling mean of published targets vs. last close $145.97. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B-

DCF

4/5

ROE

3/5

ROA

4/5

Debt/Eq

1/5

P/E

1/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

MRK +75.4% vs S&P 500 +15.9% — spread +59.5pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$145.74	+0.22	+0.15%	Above
SMA 50	$144.95	+1.02	+0.70%	Above
SMA 200	$124.74	+21.23	+17.02%	Above
EMA 9	$144.96	+1.00	+0.69%	Above
EMA 21	$145.08	+0.88	+0.61%	Above
EMA 50	$142.59	+3.38	+2.37%	Above
EMA 200	$125.70	+20.27	+16.12%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTLEAN BULLISHPower Score +2115 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%67

Momentum 25%80

Volume 20%38

Volatility 10%33

Patterns 15%62

This Week73% bullishof 11 price-based votes

4 Weeks Ago45%+28 pts since

12 Weeks Ago100%-27 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$145.74

Price vs SMA 50$144.95

Price vs SMA 200$124.74

EMA 9/21 Cross145.0/145.1

SMA 50/200Golden

ADX DirectionADX 17

Supertrend$151

Parabolic SAR$140

SMA Slope-0.050

RSI52.0

Stochastic K/D58/52

StochRSI K/D71/64

Williams %R-47

CCI16

TSI vs Signal-0.0

CMO4.1

ROC1.14%

OBV SignalDistrib

Chaikin MF-0.080

MFI50

Force Index1M

Elder Ray Bull2.71

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 52

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$147.48 / $150.05 / $154.91	S1 / S2	$142.62 / $140.05
Bollinger (20,2)	$139.78 – $151.71	Squeeze	Off
52-wk range	$81.32 – $156.92	Off 52-wk high	-7.0%
ATR (14)	$3.86 (2.6%)	Historical vol	27.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-0.5%Jan50%

-2.2%Feb30%

+1.4%Mar67%

+1.9%Apr55%

+0.5%May60%

+1.9%Jun60%

-0.5%Jul50%

+1.7%Aug65%

-0.1%Sep45%

+0.7%Oct50%

+2.6%Nov55%

+1.8%Dec60%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	MRK	S&P 500
Weekly volatility (σ, 1y)	4.32%	1.83%
Best / worst week (1y)	+14.5% / -6.6%	—
Max drawdown (5y, monthly)	-40.3%	—
1-week VaR (95%)	-5.3%	—
Beta (5y)	0.23	1.00

MRK EQUITY WEATHER (LIVE)RAINY · -19

Trend-5

Momentum+10

Volume-38

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 810 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall-18.8-9.3 vs industry

Trend-5.0-0.9 vs industry

Momentum+9.9+0.0 vs industry

Volume-38.5-55.1 vs industry

Reading	MRK	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	-18.8	-9.5	-24.0	-20.5
Trend	-5.0	-4.1	-25.6	-21.3
Momentum	+9.9	+9.9	-28.5	-15.8
Volume	-38.5	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Robert M. Davis Chairman, Chief Executive Of	$20.8M	69% equity+incentive
Dean Li, M.D., Ph.D. Executive Vice Presiden	$8.9M	64% equity+incentive
Caroline Litchfield Executive Vice President	$7.5M	62% equity+incentive
Jennifer Zachary Executive Vice President an	$5.9M	63% equity+incentive
Sanat Chattopadhyay Executive Vice President	$5.4M	61% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	76
Social	73
Governance	73
Composite ESG	74

Composite ESG Trend

Filed	8-K contents	Items
2026-10-13	Officer/Director Change	5.02
2026-08-04	Earnings Release; Exhibits	2.02,9.01
2026-05-28	Shareholder Vote	5.07
2026-05-22	Other Events; Exhibits	8.01,9.01
2026-04-30	Earnings Release; Exhibits	2.02,9.01
2026-02-03	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-12-04	Other Events; Financial Statements and Exhibits	8.01,9.01
2025-10-30	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-27 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	84 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-12 to 2026-09-30
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	2 rows · 2025-03-06 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Merck & Co., Inc. (MRK)

Institutions holding — 12 quarters

Merck & Co., Inc. (MRK)

Monthly Net Insider Flow (000 shares)

Signal Summary

Merck & Co., Inc. (MRK)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding MRK — quarterly

Institutional Put/Call — quarterly

Merck & Co., Inc. (MRK)

Where MRK Trades in the Dark

Merck & Co., Inc. (MRK)

3.8 · Employees (SEC filings)

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Balance Sheet — Full

Cash Flow Statement — Full

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Street Price Target — Trajectory

Third-Party Composite Rating

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Family Scores (site weights)

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK)